Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)

The purpose of this study is to determine if NABI-IGIV (10%) [Immune Globulin Intravenous (Human), 10%] is safe and effective in preventing serious bacterial infections (SBIs) in the treatment of patients with primary immune deficiency disorders (PIDD) when compared to historical control data.

Study Overview

• Status: Completed
• Conditions: Primary Immune Deficiency Disorders (PIDD)
• Intervention / Treatment: Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

• Study Type: Interventional
• Enrollment (Actual): 63
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama
  • Arizona
    • Phoenix, Arizona, United States, 85032
      • Precision Trials LLC
  • California
    • Los Angeles, California, United States, 90027
      • Children's Hospital of Los Angeles
  • Colorado
    • Centennial, Colorado, United States, 80112
      • 1st Allergy and Clinical Resaerch center
  • Florida
    • North Palm Beach, Florida, United States, 33408
      • Allergy Associates of the Palm Beaches
  • Georgia
    • Marietta, Georgia, United States, 30060
      • Marietta Pulmonary Medicine
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
  • Indiana
    • South Bend, Indiana, United States, 46617
      • South Bend Clinic LLP
  • Kentucky
    • Hazard, Kentucky, United States, 41701
      • Kentuky Lung Clinic, PSC
  • Maryland
    • Wheaton, Maryland, United States, 20902
      • Institute For Allergy & Asthma
  • Missouri
    • Saint Louis, Missouri, United States, 63104
      • Cardinal Glennon Children's MC
  • New York
    • Buffalo, New York, United States, 14222
      • Women's and Children's Hospital of Buffalo
  • Ohio
    • Cleveland, Ohio, United States, 44103
      • University Hospital Case Medical Center
  • Texas
    • Dallas, Texas, United States, 75230
      • Allergy/Immunology Research Center of North Texas
    • Dallas, Texas, United States, 75231
      • AARA Research
    • Irving, Texas, United States, 75063
      • Allergy, Asthma & Immunology Clinic, PA
  • Washington
    • Bellingham, Washington, United States, 98225
      • Bellingham Asthma, Allergy Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 75 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female, age ≥ 6 and ≤ 75, with a documented and confirmed pre-existing diagnosis of chronic primary immune deficiency (PIDD) with a low total immunoglobulin G (IgG) level and deficient antibody production before chronic therapy (i.e., X-linked agammaglobulinemia, common variable immunodeficiency (CVID), Hyper IgM Syndrome with immunoglobulin G (IgG) deficiency, etc).
• Currently on immune globulin intravenous (IGIV) replacement therapy at a fixed interval and dosage with a total monthly dose of immune globulin intravenous (IGIV) between 300 and 800 mg/kg that has been stable for at least 3 months prior to screening.
• Documented (within 3 months) plasma immunoglobulin G (IgG) trough level of >500 mg/dL on current immunoglobulin G (IgG) therapy [immunoglobulin G (IgG) levels may be obtained at screening if previous results not available].
• Medical records documenting infections and treatment within the previous 2 years need to be available for review.
• Subject or legal guardian(s) must have given written informed consent/assent.
• If a menstruating female, have a negative serum or urine pregnancy test within 7 days prior to the first dose of Nabi-IGIV [immune globulin intravenous (Human) 10%] and agree to use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile.

Exclusion Criteria:

• Received any blood product [other than immune globulin intravenous (IGIV)] within the last 3 months prior to screening or received any investigational agent [other than immune globulin intravenous (IGIV)] within the last four weeks prior to receiving Nabi-IGIV [immune globulin intravenous (Human) 10%].
• Known history of medically significant adverse reactions to other immunoglobulin G (IgG) or blood products.
• Known selective immunoglobulin A (IgA) deficiency, history of allergic reaction to products containing immunoglobulin A (IgA) or has a history of antibodies to immunoglobulin A (IgA).
• Known significant proteinuria and/or has a history of acute renal failure/or severe renal impairment [blood urea nitrogen (BUN) or creatinine more than 1.5 times the upper limit of normal].
• Known history or current diagnosis of deep venous thrombosis.
• Known medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), or chronic or recurrent neutropenia (absolute neutrophil count less than 500 mm3).
• Current daily use of corticosteroids (> 10 mg of prednisone equivalent /day for > 30 days), immunosuppressants or immunomodulators. (Intermittent corticosteroid use during the study is allowable, if medically necessary.)
• Known non-controllable arterial hypertension (systolic blood pressure (BP) > 160 mmHg and /or diastolic BP >100 mmHg.)
• Known anemia at screening (hemoglobin <10 g/dL).
• Subject is pregnant or lactating.
• Known history of illicit drug use within 3 months prior to the administration of the investigational product and for the study duration.
• Have any condition judged by the study physician to preclude participation in the study, including any psychological disorder, which might hinder compliance.
• Known active viral or bacterial infection or symptoms/signs consistent with such an infection within the two weeks prior to the initial dose of investigational product infusion. Subjects may be on antibiotics as long as signs/symptoms of infection have been absent for two weeks prior to the initial infusion of investigational product (IP).
• Expectation of non-compliance with the protocol procedures and visit schedule.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Nabi-IGIV Infused Every 3- or 4-Weeks

Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]; Nabi-IGIV 10% [Immune Globulin Intravenous (Human), 10%] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Serious Bacterial Infections (SBIs) Per Person-year on Treatment	Serious bacterial infections (SBIs) rate per person-years, including bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia and visceral abscess.	One year

Collaborators and Investigators

• Sponsor: ADMA Biologics, Inc.
• Investigators: Study Director: Shailesh Chavan, M.D., Biotest Pharmaceuticals Corporation

Study record dates

Study Major Dates

• Study Start: September 1, 2007
• Primary Completion (Actual): July 1, 2009
• Study Completion (Actual): July 1, 2009

Study Registration Dates

• First Submitted: October 1, 2007
• First Submitted That Met QC Criteria: October 1, 2007
• First Posted (Estimate): October 3, 2007

Study Record Updates

• Last Update Posted (Actual): July 30, 2021
• Last Update Submitted That Met QC Criteria: July 28, 2021
• Last Verified: February 1, 2012

More Information

Terms related to this study

• Keywords: PID; humoral immunity; immunodeficiency; PIDD; antibody deficiency
• Additional Relevant MeSH Terms: Immune System Diseases; Genetic Diseases, Inborn; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Immunoglobulins; Immunoglobulins, Intravenous; gamma-Globulins; Rho(D) Immune Globulin
• Other Study ID Numbers: Nabi-7101